Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2361${count})

  • Research Grant, 2019
    Astrocyte Activation as a Novel Marker of Disease Progression in Parkinson’s Disease: A PET Imaging Study

    Study Rationale:
    Brain inflammation, regulated by cells called microglia and astrocytes, has been shown to play a role in the initiation and progression of Parkinson’s disease. However, the role of...

  • LRRK2 Biology Consortium, 2019
    LRRK2 Activity and Dyskinesia Supplement

    Promising Outcomes of Original Grant:
    Our preliminary funding supported exploration of the role of striatal LRRK2 in the development of levodopa-induced dyskinesia (LID). We found that inhibiting...

  • Epidemiological Parkinson's Risk Modifiers, 2019
    Study in French Population to Identify Therapies with Repurposing Potential for Parkinson’s Disease

    Study Rationale:
    There is an urgent need to identify effective, safe and inexpensive drugs for Parkinson’s disease, and over past years, there has been increasing interest on ways to repurpose...

  • Research Grant, 2019
    Alpha-Synuclein PET Imaging Tracer Development

    Study Rationale:
    Alpha-synuclein is a protein that aggregates in several brain diseases, including Parkinson’s, dementia with Lewy bodies and multiple system atrophy. There is no established method...

  • Target Advancement Program, 2019
    Analysis and Amplification of Pathological Alpha-synuclein from Brain Tissue

    Study Rationale:                   
    Parkinson’s disease is characterized by the misfolding and accumulation of the alpha-synuclein protein in the brain. Therefore, alpha-synuclein-based disease...

  • Target Advancement Program, 2019
    GBA Stabilization through Nanobodies

    Study Rationale:
    Mutations in the GBA gene are a known genetic risk factor for Parkinson’s disease and cause reduced stability and activity of the GBA protein. This can contribute to the impairment of...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.